Telomerase reverse transcriptase promoter mutation- and O 6 -methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?

Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O -methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2021-04, Vol.147, p.84
Hauptverfasser: Gramatzki, Dorothee, Felsberg, Jörg, Hentschel, Bettina, Wolter, Marietta, Schackert, Gabriele, Westphal, Manfred, Regli, Luca, Thon, Niklas, Tatagiba, Marcos, Wick, Wolfgang, Schlegel, Uwe, Krex, Dietmar, Matschke, Jakob, Roth, Patrick, Suresh, Marian P, Kamp, Marcel A, Rushing, Elisabeth J, Pietsch, Torsten, von Deimling, Andreas, Sabel, Michael, Loeffler, Markus, Weller, Michael, Reifenberger, Guido
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 84
container_title European journal of cancer (1990)
container_volume 147
creator Gramatzki, Dorothee
Felsberg, Jörg
Hentschel, Bettina
Wolter, Marietta
Schackert, Gabriele
Westphal, Manfred
Regli, Luca
Thon, Niklas
Tatagiba, Marcos
Wick, Wolfgang
Schlegel, Uwe
Krex, Dietmar
Matschke, Jakob
Roth, Patrick
Suresh, Marian P
Kamp, Marcel A
Rushing, Elisabeth J
Pietsch, Torsten
von Deimling, Andreas
Sabel, Michael
Loeffler, Markus
Weller, Michael
Reifenberger, Guido
description Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O -methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. MGMT promoter methylation and TERT promoter mutation status were retrospectively assessed in a prospective cohort of patients with IDH-wild-type glioblastoma of the German Glioma Network (GGN) (n = 298) and an independent retrospective cohort from Düsseldorf, Germany, and Zurich, Switzerland (n = 302). In the GGN cohort, but not in the Düsseldorf/Zurich cohort, TERT promoter mutation was moderately associated with inferior outcomes in patients with MGMT promoter-unmethylated tumours (hazard ratio 1.74; 95% confidence interval: 1.07-2.82; p = 0.026). TERT promoter mutations were not associated with better outcomes in patients with MGMT promoter-methylated tumours in either cohort. The two different TERT promoter hotspot mutations (C228T and C250T) were not linked to distinct outcomes. Analysis of two independent cohorts of patients with glioblastoma did not confirm previous data, suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in patients with IDH-wild-type glioblastoma.
doi_str_mv 10.1016/j.ejca.2021.01.014
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_33631540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33631540</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-89a776092e2a82293f4d2c6d7328df1cda9f2bd107db26e3952a000bcb73e0513</originalsourceid><addsrcrecordid>eNpFkN1Kw0AQhRdBbK2-gBcyL5C4P21-vJFSf6HYm3pdNtlJuzXZDbtbJb6sr2LaKsLAgTOcj5lDyBWjMaMsudnGuC1lzClnMd3P-IQMWZbmEc0mfEDOvd9SStNsTM_IQIhEsMmYDsn3EmvboJMeweEHul6Dk8aXTrdh77bONjagg2YXZNDWRCCNggUkEDUYNl293kmjDcL96xSOzoFQHan_-cPqiGhQaRlQgUfjddAfOnQQLARs7JftL9IKQRvQ3pa6pwUEhZtOObtG01OjT12rKHQtwrrWtqilD7aRt30AwgYdgoRam_e7C3Jaydrj5a-OyNvjw3L2HM0XTy-z6TxqGc1ClOUyTROac-Qy4zwX1VjxMlGp4JmqWKlkXvFCMZqqgico8gmXfZ1FWaQC6YSJEbk-cttd0T-3ap1upOtWf02LH_QHh4I</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Telomerase reverse transcriptase promoter mutation- and O 6 -methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?</title><source>Elsevier ScienceDirect Journals</source><creator>Gramatzki, Dorothee ; Felsberg, Jörg ; Hentschel, Bettina ; Wolter, Marietta ; Schackert, Gabriele ; Westphal, Manfred ; Regli, Luca ; Thon, Niklas ; Tatagiba, Marcos ; Wick, Wolfgang ; Schlegel, Uwe ; Krex, Dietmar ; Matschke, Jakob ; Roth, Patrick ; Suresh, Marian P ; Kamp, Marcel A ; Rushing, Elisabeth J ; Pietsch, Torsten ; von Deimling, Andreas ; Sabel, Michael ; Loeffler, Markus ; Weller, Michael ; Reifenberger, Guido</creator><creatorcontrib>Gramatzki, Dorothee ; Felsberg, Jörg ; Hentschel, Bettina ; Wolter, Marietta ; Schackert, Gabriele ; Westphal, Manfred ; Regli, Luca ; Thon, Niklas ; Tatagiba, Marcos ; Wick, Wolfgang ; Schlegel, Uwe ; Krex, Dietmar ; Matschke, Jakob ; Roth, Patrick ; Suresh, Marian P ; Kamp, Marcel A ; Rushing, Elisabeth J ; Pietsch, Torsten ; von Deimling, Andreas ; Sabel, Michael ; Loeffler, Markus ; Weller, Michael ; Reifenberger, Guido</creatorcontrib><description>Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O -methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. MGMT promoter methylation and TERT promoter mutation status were retrospectively assessed in a prospective cohort of patients with IDH-wild-type glioblastoma of the German Glioma Network (GGN) (n = 298) and an independent retrospective cohort from Düsseldorf, Germany, and Zurich, Switzerland (n = 302). In the GGN cohort, but not in the Düsseldorf/Zurich cohort, TERT promoter mutation was moderately associated with inferior outcomes in patients with MGMT promoter-unmethylated tumours (hazard ratio 1.74; 95% confidence interval: 1.07-2.82; p = 0.026). TERT promoter mutations were not associated with better outcomes in patients with MGMT promoter-methylated tumours in either cohort. The two different TERT promoter hotspot mutations (C228T and C250T) were not linked to distinct outcomes. Analysis of two independent cohorts of patients with glioblastoma did not confirm previous data, suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in patients with IDH-wild-type glioblastoma.</description><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2021.01.014</identifier><identifier>PMID: 33631540</identifier><language>eng</language><publisher>England</publisher><ispartof>European journal of cancer (1990), 2021-04, Vol.147, p.84</ispartof><rights>Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33631540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gramatzki, Dorothee</creatorcontrib><creatorcontrib>Felsberg, Jörg</creatorcontrib><creatorcontrib>Hentschel, Bettina</creatorcontrib><creatorcontrib>Wolter, Marietta</creatorcontrib><creatorcontrib>Schackert, Gabriele</creatorcontrib><creatorcontrib>Westphal, Manfred</creatorcontrib><creatorcontrib>Regli, Luca</creatorcontrib><creatorcontrib>Thon, Niklas</creatorcontrib><creatorcontrib>Tatagiba, Marcos</creatorcontrib><creatorcontrib>Wick, Wolfgang</creatorcontrib><creatorcontrib>Schlegel, Uwe</creatorcontrib><creatorcontrib>Krex, Dietmar</creatorcontrib><creatorcontrib>Matschke, Jakob</creatorcontrib><creatorcontrib>Roth, Patrick</creatorcontrib><creatorcontrib>Suresh, Marian P</creatorcontrib><creatorcontrib>Kamp, Marcel A</creatorcontrib><creatorcontrib>Rushing, Elisabeth J</creatorcontrib><creatorcontrib>Pietsch, Torsten</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Sabel, Michael</creatorcontrib><creatorcontrib>Loeffler, Markus</creatorcontrib><creatorcontrib>Weller, Michael</creatorcontrib><creatorcontrib>Reifenberger, Guido</creatorcontrib><title>Telomerase reverse transcriptase promoter mutation- and O 6 -methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O -methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. MGMT promoter methylation and TERT promoter mutation status were retrospectively assessed in a prospective cohort of patients with IDH-wild-type glioblastoma of the German Glioma Network (GGN) (n = 298) and an independent retrospective cohort from Düsseldorf, Germany, and Zurich, Switzerland (n = 302). In the GGN cohort, but not in the Düsseldorf/Zurich cohort, TERT promoter mutation was moderately associated with inferior outcomes in patients with MGMT promoter-unmethylated tumours (hazard ratio 1.74; 95% confidence interval: 1.07-2.82; p = 0.026). TERT promoter mutations were not associated with better outcomes in patients with MGMT promoter-methylated tumours in either cohort. The two different TERT promoter hotspot mutations (C228T and C250T) were not linked to distinct outcomes. Analysis of two independent cohorts of patients with glioblastoma did not confirm previous data, suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in patients with IDH-wild-type glioblastoma.</description><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpFkN1Kw0AQhRdBbK2-gBcyL5C4P21-vJFSf6HYm3pdNtlJuzXZDbtbJb6sr2LaKsLAgTOcj5lDyBWjMaMsudnGuC1lzClnMd3P-IQMWZbmEc0mfEDOvd9SStNsTM_IQIhEsMmYDsn3EmvboJMeweEHul6Dk8aXTrdh77bONjagg2YXZNDWRCCNggUkEDUYNl293kmjDcL96xSOzoFQHan_-cPqiGhQaRlQgUfjddAfOnQQLARs7JftL9IKQRvQ3pa6pwUEhZtOObtG01OjT12rKHQtwrrWtqilD7aRt30AwgYdgoRam_e7C3Jaydrj5a-OyNvjw3L2HM0XTy-z6TxqGc1ClOUyTROac-Qy4zwX1VjxMlGp4JmqWKlkXvFCMZqqgico8gmXfZ1FWaQC6YSJEbk-cttd0T-3ap1upOtWf02LH_QHh4I</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Gramatzki, Dorothee</creator><creator>Felsberg, Jörg</creator><creator>Hentschel, Bettina</creator><creator>Wolter, Marietta</creator><creator>Schackert, Gabriele</creator><creator>Westphal, Manfred</creator><creator>Regli, Luca</creator><creator>Thon, Niklas</creator><creator>Tatagiba, Marcos</creator><creator>Wick, Wolfgang</creator><creator>Schlegel, Uwe</creator><creator>Krex, Dietmar</creator><creator>Matschke, Jakob</creator><creator>Roth, Patrick</creator><creator>Suresh, Marian P</creator><creator>Kamp, Marcel A</creator><creator>Rushing, Elisabeth J</creator><creator>Pietsch, Torsten</creator><creator>von Deimling, Andreas</creator><creator>Sabel, Michael</creator><creator>Loeffler, Markus</creator><creator>Weller, Michael</creator><creator>Reifenberger, Guido</creator><scope>NPM</scope></search><sort><creationdate>202104</creationdate><title>Telomerase reverse transcriptase promoter mutation- and O 6 -methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?</title><author>Gramatzki, Dorothee ; Felsberg, Jörg ; Hentschel, Bettina ; Wolter, Marietta ; Schackert, Gabriele ; Westphal, Manfred ; Regli, Luca ; Thon, Niklas ; Tatagiba, Marcos ; Wick, Wolfgang ; Schlegel, Uwe ; Krex, Dietmar ; Matschke, Jakob ; Roth, Patrick ; Suresh, Marian P ; Kamp, Marcel A ; Rushing, Elisabeth J ; Pietsch, Torsten ; von Deimling, Andreas ; Sabel, Michael ; Loeffler, Markus ; Weller, Michael ; Reifenberger, Guido</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-89a776092e2a82293f4d2c6d7328df1cda9f2bd107db26e3952a000bcb73e0513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gramatzki, Dorothee</creatorcontrib><creatorcontrib>Felsberg, Jörg</creatorcontrib><creatorcontrib>Hentschel, Bettina</creatorcontrib><creatorcontrib>Wolter, Marietta</creatorcontrib><creatorcontrib>Schackert, Gabriele</creatorcontrib><creatorcontrib>Westphal, Manfred</creatorcontrib><creatorcontrib>Regli, Luca</creatorcontrib><creatorcontrib>Thon, Niklas</creatorcontrib><creatorcontrib>Tatagiba, Marcos</creatorcontrib><creatorcontrib>Wick, Wolfgang</creatorcontrib><creatorcontrib>Schlegel, Uwe</creatorcontrib><creatorcontrib>Krex, Dietmar</creatorcontrib><creatorcontrib>Matschke, Jakob</creatorcontrib><creatorcontrib>Roth, Patrick</creatorcontrib><creatorcontrib>Suresh, Marian P</creatorcontrib><creatorcontrib>Kamp, Marcel A</creatorcontrib><creatorcontrib>Rushing, Elisabeth J</creatorcontrib><creatorcontrib>Pietsch, Torsten</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Sabel, Michael</creatorcontrib><creatorcontrib>Loeffler, Markus</creatorcontrib><creatorcontrib>Weller, Michael</creatorcontrib><creatorcontrib>Reifenberger, Guido</creatorcontrib><collection>PubMed</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gramatzki, Dorothee</au><au>Felsberg, Jörg</au><au>Hentschel, Bettina</au><au>Wolter, Marietta</au><au>Schackert, Gabriele</au><au>Westphal, Manfred</au><au>Regli, Luca</au><au>Thon, Niklas</au><au>Tatagiba, Marcos</au><au>Wick, Wolfgang</au><au>Schlegel, Uwe</au><au>Krex, Dietmar</au><au>Matschke, Jakob</au><au>Roth, Patrick</au><au>Suresh, Marian P</au><au>Kamp, Marcel A</au><au>Rushing, Elisabeth J</au><au>Pietsch, Torsten</au><au>von Deimling, Andreas</au><au>Sabel, Michael</au><au>Loeffler, Markus</au><au>Weller, Michael</au><au>Reifenberger, Guido</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telomerase reverse transcriptase promoter mutation- and O 6 -methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2021-04</date><risdate>2021</risdate><volume>147</volume><spage>84</spage><pages>84-</pages><eissn>1879-0852</eissn><abstract>Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O -methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. MGMT promoter methylation and TERT promoter mutation status were retrospectively assessed in a prospective cohort of patients with IDH-wild-type glioblastoma of the German Glioma Network (GGN) (n = 298) and an independent retrospective cohort from Düsseldorf, Germany, and Zurich, Switzerland (n = 302). In the GGN cohort, but not in the Düsseldorf/Zurich cohort, TERT promoter mutation was moderately associated with inferior outcomes in patients with MGMT promoter-unmethylated tumours (hazard ratio 1.74; 95% confidence interval: 1.07-2.82; p = 0.026). TERT promoter mutations were not associated with better outcomes in patients with MGMT promoter-methylated tumours in either cohort. The two different TERT promoter hotspot mutations (C228T and C250T) were not linked to distinct outcomes. Analysis of two independent cohorts of patients with glioblastoma did not confirm previous data, suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in patients with IDH-wild-type glioblastoma.</abstract><cop>England</cop><pmid>33631540</pmid><doi>10.1016/j.ejca.2021.01.014</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1879-0852
ispartof European journal of cancer (1990), 2021-04, Vol.147, p.84
issn 1879-0852
language eng
recordid cdi_pubmed_primary_33631540
source Elsevier ScienceDirect Journals
title Telomerase reverse transcriptase promoter mutation- and O 6 -methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A23%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telomerase%20reverse%20transcriptase%20promoter%20mutation-%20and%20O%206%20-methylguanine%20DNA%20methyltransferase%20promoter%20methylation-mediated%20sensitivity%20to%20temozolomide%20in%20isocitrate%20dehydrogenase-wild-type%20glioblastoma:%20is%20there%20a%20link?&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Gramatzki,%20Dorothee&rft.date=2021-04&rft.volume=147&rft.spage=84&rft.pages=84-&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2021.01.014&rft_dat=%3Cpubmed%3E33631540%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33631540&rfr_iscdi=true